Mature astrocytes and other glial cells produce the monomeric intermediate filament protein known as GFAP (glial fibrillary acidic protein), which is not present outside of the central nervous system. Most commonly, increased GFAP immunoreactivity (also known as astrocytic activation) is understood to be a relatively slow-developing correlate of neural damage or an index of gliosis.
Brief information
- Name: Glial fibrillary acidic protein
- Target Synonym: Glial Fibrillary Acidic Protein, Intermediate Filament Protein, ALXDRD, FLJ45472
- Number of Launched Drugs: 1
- Number of Drugs in Clinical Trials: 1
- Latest Research Phase: Approved
Part of bioactivity data
Immobilized Mouse GFAP, His Tag (Cat. No. GFP-M5148) at 1 μg/mL (100 μL/well) can bind GFAP Monoclonal Antibody with a linear range of 0.4-25 ng/mL (QC tested). Image Credit: ACROBiosystems Inc.
Immobilized Human GFAP, His Tag (Cat. No. GFP-H5143) at 1 μg/mL (100 μL/well) can bind GFAP Monoclonal Antibody with a linear range of 0.8-25 ng/mL (QC tested). Image Credit: ACROBiosystems Inc.
Synonym name
Glial fibrillary acidic protein